Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
48,446,966

-0.41 (-1.43%)

Updated Aug 16, 2024 04:01 PM ET

After-Market: $28.27 -0.03 (-0.11%) 5:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Quality Dividend ETFs for Turbulent Times

Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.

    Agilent Boosts Market Share With FDA Nod to New Cancer Test

    Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.

      Arpita Dutt headshot

      Pharma Stock Roundup: J&J Drug Gets CRL, Label Expansion for Merck and BMY Drugs

      Industry heavyweights like Johnson & Johnson (JNJ), Merck and Bristol-Myers were in the news related to regulatory updates.

        Merck's Keytruda Gets FDA Nod for Advanced Gastric Cancer

        Merck's (MRK) Keytruda received FDA approval for advanced gastric cancer, making it the tenth new indication approved for Keytruda.

          Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

          Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

            Swarup Gupta headshot

            Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com

            The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.

              Cancer Space Update: Mixed Week for Pfizer, Roche Falters

              Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

                Arpita Dutt headshot

                Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

                Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

                  Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

                  Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

                    Can Pfizer (PFE) Prove to be an Apt Value Investment?

                    Let's find out if Pfizer, Inc. (PFE) stock is a good choice for value-oriented investors right now

                      Mylan Down 24% Year to Date: What's Troubling the Stock?

                      Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

                        Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

                        Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

                          Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

                          : Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

                            Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

                            Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.

                              Pfizer Xtandi Succeeds in Early Stage Prostate Cancer Study

                              Pfizer's (PFE) prostate cancer drug Xtandi met the primary endpoint in a late-stage study, which can expand the label of the drug to include early-stage patients.

                                Arpita Dutt headshot

                                Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO

                                Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.

                                  Ryan McQueeney headshot

                                  Why Did Pfizer (PFE) Stock Pop Today?

                                  Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.

                                    The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

                                    The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

                                      Mark Vickery headshot

                                      Top Analyst Reports for Apple, Pfizer & Carnival

                                      Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Pfizer (PFE) and Carnival (CCL).

                                        Bristol-Myers Reports Positive Results from Melanoma Study

                                        Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.

                                          AbbVie's RA Candidate Meets Primary Endpoint in Phase III

                                          AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.

                                            Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable

                                            Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).

                                              3 Excellent Dividend ETFs for Turbulent Times

                                              Consider these 3 Dividend ETFs for your portfolio to battle market uncertainty.

                                                Bristol-Myers' Opdivo Study Meets Early Success, Stock Up

                                                Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.

                                                  Swarup Gupta headshot

                                                  Dow 30 Stock Roundup: UTX to Buy Rockwell Collins, Merck Secures EU Keytruda Approval

                                                  The Dow endured significant losses over a holiday-shortened trading week.